文献速递系统性红斑狼疮

SGLT2抑制剂通过减轻炎症和增强自噬改善狼疮肾炎足细胞损伤

SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy.
PubMed 文献 · Ann Rheum Dis · 2023-07-24

在狼疮倾向MRL/lpr小鼠中,恩格列净治疗使抗dsDNA IgG特异性抗体、血清肌酐和蛋白尿水平明显降低,肾小球和肾小管间质损伤均减轻;SGLT2敲除足细胞系显示恩格列净通过减轻炎症和降低mTORC1活性增强自噬来减轻足细胞损伤。9例狼疮肾炎患者使用SGLT2抑制剂随访超过2个月,蛋白尿从29.6%降至96.3%的显著下降,eGFR相对稳定。

要点

  • 恩格列净降低MRL/lpr小鼠抗dsDNA IgG抗体、血清肌酐和蛋白尿水平。
  • 恩格列净减轻MRL/lpr小鼠肾小球和肾小管间质损伤。
  • 9例狼疮肾炎患者用SGLT2抑制剂后蛋白尿从29.6%降至96.3%,eGFR相对稳定。

核心结论

  • 本研究证实SGLT2抑制剂在狼疮小鼠中具有肾脏保护作用,为改善狼疮肾炎等经典自身免疫性肾脏疾病的非免疫抑制治疗提供了更多证据。

研究设计与样本

  • 对狼疮倾向MRL/lpr小鼠给予恩格列净治疗以探索SGLT2抑制剂的肾脏保护潜力。
  • 使用CRISPR/Cas9系统构建SGLT2敲除单克隆足细胞系以检查细胞和分子机制。
  • 9例狼疮肾炎患者接受SGLT2抑制剂治疗并随访超过2个月。

主要发现

  • 恩格列净治疗的MRL/lpr小鼠抗dsDNA IgG特异性抗体、血清肌酐和蛋白尿水平明显降低。
  • 恩格列净给药减轻了MRL/lpr小鼠的肾小球和肾小管间质损伤。
  • 狼疮肾炎患者肾活检样本和肾炎MRL/lpr小鼠中SGLT2表达水平升高并与减少的synaptopodin共定位。
  • 恩格列净通过减轻炎症和降低mTORC1活性增强自噬来减轻足细胞损伤。
  • 9例狼疮肾炎患者使用SGLT2抑制剂与蛋白尿从29.6%至96.3%的显著下降相关,eGFR在治疗期间相对稳定。

关键数值与推荐

  • 9例狼疮肾炎患者使用SGLT2抑制剂后蛋白尿从29.6%降至96.3%。
  • 9例狼疮肾炎患者治疗期间eGFR相对稳定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The protective role of sodium glucose cotransporter 2 (SGLT2) inhibitors in renal outcomes has been revealed by large cardiovascular outcome trials among patients with type 2 diabetes. However, the effect of SGLT2 inhibitors on lupus nephritis (LN) and its underlying mechanisms remain unknown. METHODS: We applied empagliflozin treatment to lupus-prone MRL/lpr mice to explore the renal protective potential of SGLT2 inhibitors. An SGLT2 knockout monoclonal podocyte cell line was generated using the CRISPR/Cas9 system to examine the cellular and molecular mechanisms. RESULTS: In MRL/lpr mice treated with empagliflozin, the levels of mouse anti-dsDNA IgG-specific antibodies, serum creatinine and proteinuria were markedly decreased. For renal pathology assessment, both the glomerular and tubulointerstitial damages were lessened by administration of empagliflozin. The levels of SGLT2 expression were increased and colocalised with decreased synaptopodin in the renal biopsy samples from patients with LN and MRL/lpr mice with nephritis. The SGLT2 inhibitor empagliflozin could alleviated podocyte injury by attenuating inflammation and enhanced autophagy by reducing mTORC1 activity. Nine patients with LN treated with SGLT2 inhibitors with more than 2 months of follow-up showed that the use of SGLT2 inhibitors was associated with a significant decrease in proteinuria from 29.6% to 96.3%. Moreover, the estimated glomerular filtration rate (eGFR) was relatively stable during the treatment with SGLT2 inhibitors. CONCLUSION: This study confirmed the renoprotective effect of SGLT2 inhibitors in lupus mice, providing more evidence for non-immunosuppressive therapies to improve renal function in classic autoimmune kidney diseases such as LN.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Zhao XY, Li SS, He YX, et al. SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy. Ann Rheum Dis. 2023. PMID: 37487609. doi:10.1136/ard-2023-224242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。